StockData

Rigel Pharmaceuticals vs Syndax Pharmaceuticals

RIGL and SNDX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How RIGL and SNDX compare

Rigel Pharmaceuticals and Syndax Pharmaceuticals are about the same size, with market caps of $802M and $822M.

Syndax Pharmaceuticals grew revenue faster over the last twelve months (160% versus 3.3% for Rigel Pharmaceuticals).

Rigel Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 116% compared with −72.3% at Syndax Pharmaceuticals.

Rigel Pharmaceuticals scores higher on the StockData Score (11 against 3 for Syndax Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricRIGLSNDX
Size and price
Market cap$802M$822M
Share price$42.92$9.20
Change, 1 year2.3%−44.6%
Change, 5 years54.9%−44.2%
Beta (5Y)2.151.72
Employees174298
StockData Score
Total score11 (better)3
Valuation score3 (better)1
Growth score11
Performance score4 (better)0
Health score3 (better)1
Dividend score00
Valuation
P/E2.7×–
P/S2.9×2.8× (better)
P/B1.9×–
EV/EBITDA7.9×–
Growth
Revenue growth (TTM)3.3%160% (better)
Revenue growth, 5Y average22.1%158% (better)
Net income growth (TTM)229%–
EPS growth (TTM)196%–
Profitability
Gross margin91.4%–
Operating margin31.5% (better)−61.7%
Net margin116% (better)−72.3%
Return on equity127% (better)−426%
Return on invested capital57.4%–
Financial health
Interest coverage15.0× (better)−44660.0×
Current ratio1.944.69 (better)
Altman Z-score3.64 (better)−2.30
Piotroski F-score7 (better)3
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions87.7%121%
Held by insiders3.3%1.8%
Insider net buying, 12 months−$306K (better)−$2.9M
Short interest, % of float14.0%21.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.